Know Cancer

or
forgot password

A Phase II Study of Continuous Versus Syncopated Dosing of CC-5013 for the Treatment of Refractory Multiple Myeloma


Phase 2
18 Years
N/A
Not Enrolling
Both
Multiple Myeloma

Thank you

Trial Information

A Phase II Study of Continuous Versus Syncopated Dosing of CC-5013 for the Treatment of Refractory Multiple Myeloma

Inclusion Criteria


- History of histologically documented multiple myeloma with relapsed or resistant
disease

- Pregnant or nursing women may not participate. Women of childbearing potential must
have a negative pregnancy documented within one week of registration. Women of
reproductive potential may not participate unless they have agreed to use an
effective contraceptive method.

- Signed written informed consent and willingness to meet follow-up schedule and study
procedure obligations

Type of Study:

Interventional

Study Design:

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Principal Investigator

Robert Knight, MD

Investigator Role:

Study Director

Investigator Affiliation:

Celgene Corporation

Authority:

United States: Food and Drug Administration

Study ID:

CC-5013-MM-008

NCT ID:

NCT00051116

Start Date:

May 2002

Completion Date:

October 2006

Related Keywords:

  • Multiple Myeloma
  • Multiple Myeloma
  • Revimid
  • CC5013
  • CC-5013
  • Multiple Myeloma
  • Neoplasms, Plasma Cell

Name

Location

Myeloma Institute University of Arkansas for Medical SciencesLittle Rock, Arkansas  72205